Cost-minimization analysis Phesgo model

The main objective of this study is to determine whether the employment of fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (or Phesgo) to treat metastatic HER2-positive breast cancer patients would minimize costs compared to the traditional treatment of separate intravenous doses of pertuzumab and trastuzumab in Peru. To achieve this, we used EsSalud (the social security health insurance) data and assessed it through a mixed strategy, which consisted of a quantitative and a qualitative approach. The first one aimed to calculate the direct (non-drug consumables, drugs, and healthcare professionals) and indirect costs of both treatments to develop a comparison, whilst the second aimed to validate information and internalize the procedure in an EsSalud context.
Overall, we found that the usage of Phesgo would be cost saving in EsSalud’s context. Specifically, we found three main insights. Firstly, the savings produced from switching from the traditional intr..., , , # Data from: Cost-minimization analysis Phesgo model

[https://doi.org/10.5061/dryad.pc866t1wn](https://doi.org/10.5061/dryad.pc866t1wn)

We use public information from the Peruvian social health security. We use the following sources of data:

Hospital administrative documents: We retrieved the annual salaries of nurses and pharmaceutical chemists and accessed the list of EsSalud strategic purchases. The latter list included the prices and specific characteristics (size, type, etc.) of drugs, non-drug consumables, and medical equipment for cancer treatment. Finally, the pertuzumab and trastuzumab monthly consumption series and the number of chemotherapy couches were provided by EsSalud. The latter pieces of information were at the hospital level and allowed us to estimate both the number of treated patients and the nationwide attention capacity.

Clinical practice guidelines: The HER2-positive metastatic and non-metastatic breast cancer clinical practice guidelines contain the step-by-...